NCRI 2018 | Reactivating the host immune response against cancer: new genetic discoveries

Sergio Quezada

In this interview, Sergio Quezada, PhD, from University College London, London, UK, discusses the development of monoclonal antibodies as an effective therapy for the treatment of metastatic melanoma. Dr Quezada discusses how the genetic complexity of malignant tumors can be recognized and exploited by the immune system, specifically by the activation of T-cells, before intoducing the challenges and future outlooks in finding a pathway to rationalize the usage, timing and combinations of effective drug combinations. This video was recorded at the 2018 National Cancer Research Institute (NCRI) Cancer Conference, held in Glasgow, UK.

Share this video